Journal article
Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults
T Nolan, M O'Ryan, J Wassil, V Abitbol, P Dull
Vaccine | Published : 2015
Abstract
Vaccination programs employing capsular-based meningococcal vaccines have proved successful in a variety of settings globally since first introduced over 40 years ago. Similar successes have been demonstrated using meningococcal vaccines for use against serogroup B (MenB) outbreak strains but the diversity of MenB strains has limited vaccine use outside targeted geographic regions. MenB continues to be a significant cause of outbreaks in adolescents and young adults, as recently demonstrated in university settings in the US (Princeton, New Jersey and Santa Barbara, California) and has the potential for hyperendemic disease levels such as currently experienced in Québec and the United Kingdom..
View full abstractGrants
Funding Acknowledgements
This review was funded by Novartis Vaccines and Diagnostics. James Wassil and Veronique Abitbol are employees of Novartis Vaccines and Diagnostics. Peter Dull was an employee of Novartis Vaccines and Diagnostics at the time the manuscript was written and is currently at the Bill and Melinda Gates Foundation. Terry Nolan and Miguel O'Ryan did not receive any monetary incentives from the sponsor with respect to this manuscript. Both their institutions have received research contracts from Novartis to carry out clinical studies of MenB vaccine. The authors have no financial relationships relevant to this review article to disclose.